Indaptus Therapeutics Inc Stock Price, News & Analysis

Indaptus Therapeutics (Nasdaq: INDP) reported third quarter 2025 results and a corporate update on Nov 12, 2025. Key clinical and financing highlights include completion of a six-participant Safety Lead-In combining Decoy20 and tislelizumab, which the Safety Review Committee deemed tolerable at the current dose and schedule, while enrollment is paused pending further efficacy evaluations.

Financials: the company reported $5.8M cash at Sept 30, 2025, raised $2.3M via an at-the-market facility in Sept 2025, converted $5.7M of June 2025 promissory notes in July 2025, and expects cash to fund operations into Q1 2026.

Indaptus Therapeutics (Nasdaq: INDP) provided updates on its INDP-D101 clinical trial evaluating Decoy20. A patient receiving Decoy20 monotherapy achieved a Partial Response with reduced liver metastases in urothelial cancer, though the response was not sustained. The company has also initiated combination therapy with tislelizumab, dosing 7 patients in the initial safety cohort.

Of the first three evaluable combination therapy patients, one showed stable disease while two experienced disease progression. Additionally, Indaptus raised $5.7 million through convertible promissory notes and warrants, which were later converted into common stock and pre-funded warrants in July 2025.

Indaptus Therapeutics (Nasdaq: INDP) announced that CEO Jeffrey A. Meckler will deliver a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation is scheduled for September 8, 2025, at 3:30pm ET in the Kennedy I room at the Lotte New York Palace Hotel.

Investors can access the presentation through a live webcast on the company's investor relations website, with a replay available for approximately 90 days. One-on-one meetings with Mr. Meckler will be available throughout the conference.

Indaptus Therapeutics (Nasdaq: INDP) has reported its Q2 2025 financial results and provided significant corporate updates. The company has reached a major clinical milestone by dosing its first patient in the Phase 1b/2 combination study of Decoy20 with PD-1 checkpoint inhibitor tislelizumab.

Financial highlights include R&D expenses of $2.2 million for Q2 2025, up from $1.7 million in Q2 2024, and a net loss per share of $9.09. The company strengthened its balance sheet by raising $5.7 million through convertible notes and warrants, which were converted to equity in July 2025. Cash position stands at $6.2 million, expected to fund operations into Q4 2025.

Indaptus Therapeutics (Nasdaq: INDP), a clinical stage biotechnology company, has announced an additional sale of $3.4 million in convertible promissory notes and warrants. Combined with a prior sale of $2.3 million, the company has raised total gross proceeds of $5.7 million in this offering.

The notes carry a 6% annual interest rate and will mature on July 28, 2026. They will convert to common stock at the earlier of 30 days after a reverse split effectiveness or one year from issuance. The conversion price will be 80% of the average closing price over five trading days, capped at $11.20. Warrants for 200% of conversion shares will be issued post-conversion and stockholder approval.

Paulson Investment Company, LLC serves as the exclusive placement agent. The proceeds will fund research and development, including a Phase 1b/2 clinical trial, working capital, and general corporate purposes. The securities were offered through a private placement under Section 4(a)(2) of the Securities Act and Rule 506(c) of Regulation D.

Indaptus Therapeutics (Nasdaq: INDP), a clinical stage biotechnology company, has announced a 1-for-28 reverse stock split effective after market close on June 26, 2025. The stock will begin trading on a split-adjusted basis on June 27, 2025, under the same symbol "INDP" but with a new CUSIP number.

The reverse split, approved by stockholders on June 10, 2025, aims to regain Nasdaq listing compliance and attract institutional investors. The split will reduce outstanding shares from approximately 16 million to 572 thousand. Proportionate adjustments will be made to outstanding options and warrants, with cash payments issued for fractional shares based on the closing price on June 26, 2025.

Indaptus Therapeutics (NASDAQ: INDP) has secured $2.3 million through a private placement of convertible notes and warrants, led by a healthcare-focused institutional investor, as part of a larger offering targeting up to $5 million. The notes, maturing on July 28, 2026, carry a 6% annual interest rate and will convert to common stock at 80% of the average closing price over five trading days, capped at $0.40 per share. Investors will receive warrants to purchase 200% of conversion shares, exercisable for five years at the notes' conversion price. The proceeds will fund research and development, including a Phase 1b/2 clinical trial, working capital, and general corporate purposes. Paulson Investment Company is serving as the exclusive placement agent for this offering.

Indaptus Therapeutics (NASDAQ: INDP) has initiated dosing in a new Phase 1b/2 clinical trial arm evaluating Decoy20 in combination with BeOne's PD-1 checkpoint inhibitor tislelizumab. The study focuses on patients with advanced solid tumors who either previously received checkpoint inhibitor treatment or have tumors typically unresponsive to checkpoint inhibitors. The trial aims to assess safety, optimize dosing, and evaluate preliminary anti-tumor activity. Preclinical data has shown synergistic effects between Decoy20 and checkpoint inhibitors, suggesting potential enhanced immune responses. The company believes this combination therapy could benefit patients who don't respond to traditional checkpoint inhibitor treatments.

Indaptus Therapeutics (NASDAQ: INDP) reported Q1 2025 financial results and provided corporate updates. Key highlights include the initiation of a Phase 1b/2 combination study of Decoy20 with PD-1 checkpoint inhibitor Tislelizumab. The company has enrolled 32 patients in weekly dosing trials, showing Decoy20 is well-tolerated with encouraging stable disease cases. Financial results show R&D expenses increased to $2.8M (vs $1.6M in Q1 2024), while G&A expenses decreased to $1.8M (vs $2.4M). Loss per share improved to $0.32 (vs $0.45). Cash position stands at $3.9M as of March 31, 2025, down from $5.8M in December 2024. The company implemented a cost-reduction plan and expanded its patent portfolio in China, Japan, and Israel, but will need additional capital beyond Q2 2025.